Slingshot members are tracking this event:
Aimmune Therapeutics (AIMT) Provides Update on Ongoing AR101 Phase 3 Program for Peanut Allergy Based on FDA Feedback
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
|Community voting in process
Slingshot Insights Explained
Feb 16, 2017
Don’t see a project related to the catalyst you care about?
Related Keywords Ar101, Phase 3 Program, Peanut Allergy